When was Resolution Therapeutics founded?

Resolution Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Resolution Therapeutics located?

Resolution Therapeutics is headquartered in Edinburgh, United Kingdom. It is registered at 8 Bloomsbury Street, London, England, WC1B 3SR.

Which legal entities is Resolution Therapeutics associated with?

Resolution Therapeutics is associated with RESOLUTION THERAPEUTICS LIMITED.

How many employees does Resolution Therapeutics have?

As of Sep 30, 2026, the latest employee count at Resolution Therapeutics is 75.

Is Resolution Therapeutics a funded company?

Resolution Therapeutics is a funded company, having raised a total of $120M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 02, 2020.

When was the latest funding round of Resolution Therapeutics?

Resolution Therapeutics' latest funding was a $***** Series B round on Oct 03, 2024, with participation from 1 investor.

What is the annual revenue of Resolution Therapeutics?

Annual revenue of Resolution Therapeutics is less than £1M as on Mar 31, 2025

Where does Resolution Therapeutics rank among its competitors?

Resolution Therapeutics ranks 78th amongst 441 active competitors, of which 154 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Resolution Therapeutics?

Resolution Therapeutics' top competitors include Upstream Bio, Odyssey and Septerna. Among them, Drug Farm secured the most recent funding round in July, 2026.

Resolution Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Resolution Therapeutics is a series B company based in Edinburgh (United Kingdom), founded in 2017 by John Campbell and Stuart Forbes. It operates as a Developer of macrophage cell therapy for the treatment of inflammatory & liver diseases. Resolution Therapeutics has raised $120M in funding from Syncona. The company has 441 active competitors, including 154 funded and 98 that have exited. Its top competitors include companies like Upstream Bio, Odyssey and Septerna.

Company Details

Developer of macrophage cell therapy for the treatment of inflammatory & liver diseases. The company has developed cell therapies based on its proprietary platform of macrophage biology, cell engineering, and manufacturing processes. The therapeutic solutions enhance body immunity power and provide prevention solutions for inflammatory organ damages. It also helps in sterilising any wounds and promotes organ repair.

Website: resolution-tx.com
Email ID: *****@resolution-tx.com
Registered Address: 8 Bloomsbury Street, London, England, WC1B 3SR

Key Metrics

Founded Year

2017

Location

Edinburgh, United Kingdom

Stage

Series B

Total Funding

$120M in 2 rounds

Latest Funding Round

Series B, Oct 03, 2024, $*****

Investors

Syncona

Ranked

78^th among 441 active competitors

Annual Revenue

£0 - £1M as on Mar 31, 2025

Employee Count

75 as on Sep 30, 2026

Similar Companies

Upstream Bio & 452 more

View Resolution Therapeutics' full profile

Resolution Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
RESOLUTION THERAPEUTICS LIMITED CIN: 11112568 , United Kingdom, Active	Dec 13, 2017	£0 - £1M (As on Mar 31, 2025)	6 (As on Mar 31, 2021)

Resolution Therapeutics has raised a total funding of $120M over 2 rounds. Its first funding round was on Dec 02, 2020. Its latest funding round was a Series B round on Oct 03, 2024 for $*****. 1 investor participated in its latest round. Resolution Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Resolution Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 03, 2024	3143436	Series B	6457742	4000207	4290691	1709312
Dec 02, 2020	5110338	Series A	5049227	1012947	Syncona	7780381

Access funding benchmarks and valuations. Sign up today!

View details of Resolution Therapeutics's funding rounds and investors

The founders of Resolution Therapeutics are John Campbell and Stuart Forbes.

Here are the details of Resolution Therapeutics' key team members:

John Campbell: Co-Founder of Resolution Therapeutics.
Contact Info: 1 email address
Stuart Forbes: Co-Founder of Resolution Therapeutics.
Contact Info: 1 email address

View details of Resolution Therapeutics's Founder profiles and Board Members

Resolution Therapeutics' employee count trend

Resolution Therapeutics has 75 employees as of Sep 26. Here is Resolution Therapeutics's employee count trend over the years:

Employee count trend for Resolution Therapeutics

Uncover Resolution Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Resolution Therapeutics include Upstream Bio, Odyssey and Septerna. Here is the list of Top 10 competitors of Resolution Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	67/100
2nd	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
3rd	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
4th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
5th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
6th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	65/100
7th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	64/100
8th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
9th	Vyome Therapeutics 2010, Princeton (United States), Public	Developer of therapeutics for the immuno-inflammatory conditions	$62.9M	Perceptive Advisors, Iron Pillar & 11 others	64/100
10th	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 13 others	64/100
78th	Resolution Therapeutics 2017, Edinburgh (United Kingdom), Series B	Developer of macrophage cell therapy for the treatment of inflammatory & liver diseases	$120M	Syncona	48/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Resolution Therapeutics's competitors? Click here to see the top ones

Resolution Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Resolution Therapeutics's sector:

Free

Gastroenterology - Sector Report

Edition: September, 2026 (69 Pages)

View all reports related to Resolution Therapeutics

Media has covered Resolution Therapeutics for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.